Tasurgratinib

Phase 1Small molecule

Eisai

Tasurgratinib is one of 23 small molecule programs targeting Hepatic Impairment. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatic ImpairmentRecruiting

Hepatic ImpairmentPhase 1

Recruiting

Competition

Competitive Landscape

22 competitors in Hepatic Impairment

#DrugCompanyPhaseTrials

Vanflyta

Daiichi Sankyo

Phase 1

1 2

Gomekli

SSpringWorks Therapeutics, Inc.

Phase 1

1 3

Luye

Ascentage Pharma Group Inc.

Phase 1

1 4

Beqalzi

BBeOne Medicines

Phase 1

1 5

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 6

Lipaglyn

ZZydus Therapeutics Inc.

Phase 1

1 7

ASTX727

Taiho Oncology, Inc.

Phase 1

1 8

Casdatifan

Arcus Biosciences

Phase 1

1 9

Atirmociclib

Pfizer

Phase 1

1 10

PF-07328948

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Hepatic Impairment

NCT04271488

Clinical

Trials by Indication[1]

Hepatic Impairment1 trial

An Open-label Parallel-Group Study to Evaluate Pharmacokinetics of E7090 and Its Metabolite in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Recruiting· Eisai logo

Eisai·Phase 1·NCT04271488·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tasurgratinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tasurgratinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tasurgratinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eisai company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Eisai

Tasurgratinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hepatic Impairment1 trial

References

Drug Info

Quick Facts

Related News